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Abstract
Background: Despite decades of intensive research, to date, there is no accepted diagnosis for Parkinson’s disease
(PD) based on biochemical analysis of blood or CSF. However, neurodegeneration in the brains of PD patients begins
several years before the manifestation of the clinical symptoms, pointing to serious flaw/limitations in this approach.
Results: To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for PD, we generated
specific antibodies directed against wide array of α-syn species, namely total-, oligomeric- and phosphorylated-Ser129-
α-syn (t-, o- and p-S129-α-syn). Next we sought to employ our antibodies to develop highly specific ELISA assays to
quantify α-syn species in biological samples. Finally we verified the usefulness of our assays in CSF samples from 46 PD
patients and 48 age-matched healthy controls. We also assessed the discriminating power of combining multiple CSF
α-syn species with classical Alzheimer’s disease biomarkers. The combination of CSF o-/t-α-syn, p-S129-α-syn and p-tau
provided the best fitting predictive model for discriminating PD patients from controls. Moreover, CSF o-α-syn levels
correlated significantly with the severity of PD motor symptoms (r = -0.37).
Conclusion: Our new ELISA assays can serve as research tools to address the unmet need for reliable CSF biomarkers
for PD and related disorders.
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Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder after Alzheimer’s disease. PD
is characterized by a large time-gap between the begin-
ning of the neurodegenerative processes and the onset
of clinical manifestations [1]. However, its diagnosis is
primarily based on motor-related clinical criteria. The
natural history of the disease includes an initial asymp-
tomatic stage followed by a long pre-motor phase; finally,
when the classical motor symptoms appear, a minimum of
30 % of nigral dopaminergic neurons have already degen-
erated [2–5]. Therefore, there is an urgent need for the
discovery of reliable biomarkers for PD diagnosis and
prognosis. Toward this aim, recent intensive investigations
have attempted to identify biomarker (s) to enable an early
diagnosis of PD, preferably during the pre-motor phase.
And since molecular changes in the brain can be
reflected in the CSF proteome, this makes CSF an ideal
source of reliable biomarkers [6]. Aggregated and
hyper-phosphorylated forms of alpha-synuclein (α-syn)
protein at S129 are the major components of Lewy
bodies (LBs) and Lewy neurites and constitute the hall-
mark pathology in the brains of patients with PD and
dementia with Lewy bodies [7]. Although the accumulation
of α-syn is central to the development of synucleinopa-
thies, the precise pathophysiological mechanism remains
uncertain [8]. Of the different species of α-syn, intermedi-
ate oligomers/protofibrils are thought to be the major
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neurotoxic species [9, 10]. Therefore, developing thera-
peutic and diagnostic strategies that target these species is
of paramount importance. Several retrospective studies
have explored CSF α-syn as a putative biomarker for PD. A
clear trend of lower CSF t-α-syn levels or marginally higher
p-S129-α-syn/t-α-syn ratio in PD have been reported, al-
though a large overlap between PD and control groups was
noted [11–17]. Clearly, from previous studies it is evident
that t-α-syn levels alone cannot discriminate individual pa-
tients with synucleinopathies from healthy individuals or
those with other neurodegenerative diseases. Soluble α-syn
oligomers (o-α-syn) have been increasingly linked to syn-
aptic and neuronal degeneration [18] . The exact mechan-
ism by which α-syn oligomers cause neuronal cell death is
not fully elucidated. It has been shown that soluble o-α-syn
is elevated in brain homogenates from PD and DLB cases
compared with controls [19, 20]. Interestingly, we have
previously reported that CSF o-α-syn levels were signifi-
cantly higher in PD patients compared with other neuro-
logical disorders [14, 16]. CSF o-α-syn levels and o-α-syn/
t-α-syn ratios were found to be substantially higher in pa-
tients with PD, including those with mild and early-stage
disease, compared with controls [14, 16, 21–23].
Considering the findings presented above, it’s crucial to
adopt precise strategies/methods capable to specifically
quantify α-syn neurotoxic species in biological samples. In
this context, we demonstrated the development of specific,
sensitive and reliable ELISA assays using our antibodies to
assess different species of α-syn (t-, o- and p-S129-α-syn)
in different biological samples. The provision of such reli-
able immunoassays is not only valuable for the discovery of
ideal CSF biomarkers but also for a better understanding
of the underlying pathophysiological process in PD and re-
lated disorders. Next, to explore the potential of our novel
assays, we employed them to quantify different species of
α-syn in CSF from a cohort of PD patients and age-
matched healthy controls (HC). Finally, we investigated the
usefulness of combining several biomarkers that reflect
different pathogenic pathways, including AD classical bio-
markers (total-tau (t-tau), phosphorylated-tau (p-tau) and
amyloid-beta-42 (Aβ-42)), as candidate CSF biomarkers for
PD and related disorders.
Results
Development and characterization of our anti-α-syn
antibodies
Our mouse monoclonal antibody, Syn-O2, specifically
recognizes early “soluble oligomers” and late aggregates
“amyloid fibrils” of α-syn (Fig. 1a, b), and has a high
binding affinity for o-α-syn (IC50 120 pM and KD 9.6 ×
10−11 M) [24]. It exclusively bound to α-syn aggregates
(amyloid fibrils and soluble oligomers) without cross-
reactivity with monomers or fibrils generated from other
amyloid proteins including β-syn, γ-syn, β-amyloid, tau,
islet amyloid polypeptide (IAPP) or ABri (Fig. 1a, b). In im-
munohistochemical studies, Syn-O2 stained underappreci-
ated small intra- and extracellular micro-aggregates and very
thin neurites in PD and DLB cases that were not observed
with generic pan antibodies (Syn-1 or KM51) that recognize
linear epitope. Both classical Lewy neurites defined as elon-
gated structures within neuronal processes, and Lewy neur-
ites in the form of beaded strings; swollen/bulging neurites
and long, thin threads were also stained by Syn-O2 (Fig. 1c,
d) (for details see Additional file 1). The mAb,11D12, and a
sheep polyclonal-antibody, Syn-140, both recognized
different forms/species of α-syn including monomeric-, olig-
omeric-, protofibrillar-, nitrated- and phosphorylated-S129-
α-syn, as well as full-length and N- or C-terminal truncated
forms of α-syn (Fig. 1e-g). Finally, PS129, a mouse mAb was
specific for p-S129-α-syn (Fig. 1h).
Development of new ELISA assays for measuring different
species of α-syn
We developed, validated and optimized a new sandwich-
type ELISA for measuring t-α-syn levels in human CSF.
Assay conditions were first optimized using different con-
centrations of the capture antibody Syn-140 (sheep anti-
α-syn polyclonal antibody). Based on its sensitivity and
background signal, 0.1 μg/ml of the capture antibody was
selected for subsequent assays. The detection limit of the
assay was as low as 50 pg/ml, which is 20-fold less than
the concentration detected in human CSF (Fig. 2a). The
standard curve for the ELISA assay was constructed using
different concentrations of recombinant human α-syn in
solution. Serial dilutions of recombinant human β-syn and
γ-syn were also included as negative controls (Fig. 2b).
The inter-assay coefficient of variation (CV) examined
over >10 plates was < 10 % (Fig. 2c). As illustrated in
(Fig. 2d), our assay permitted the direct quantification of
native α-syn in biological samples such as human CSF and
Tg mouse-brain lysates (for details see Additional file 1).
α-Syn was detected in Tg mice and human CSF, whereas
no signal was observed in WT or KO lysates (Fig. 2d).
Moreover, recovery rates were determined by spiking re-
combinant α-syn into human CSF. Our assay consistently
featured a mean recovery rate > 90 % (Fig. 2e).
We followed a similar protocol for p-S129-α-syn-spe-
cific ELISA, where Syn-140 was used as the capture anti-
body and PS129 was used as the reporter. To address the
issue of specificity, serial dilutions of recombinant human
p-S129-α-syn and non-phosphorylated α-syn were tested,
and signal was detected only with the p-S129-α-syn
(Fig. 3a). Using similar criteria (sensitivity, reproducibility
and background signal), optimal conditions were adopted
for the assay (Fig. 3b). The limit of detection was as low as
20 pg/ml, and a standard curve with R2 of 0.999 was gen-
erated (Fig. 3b), whereas, the inter-assay CV was < 15 %
(Fig. 3c). To explore the assay suitability for quantifying
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p-S129-α-syn in biological fluids, multiple concentra-
tions of recombinant human p-S129-α-syn were spiked
into human CSF. The mean recovery rates were
between 95 and 97 % (Fig. 3d).
Following the complete characterization of our
conformation-specific monoclonal antibody Syn-O2 as
described above, we developed and optimized novel specific
ELISA for measuring o-α-syn in human CSF. Similarly, our
oligomeric ELISA is based on a conventional sandwich
ELISA system, where o-α-syn is captured using our highly
specific anti-o-α-syn mAb; Syn-O2. Multiple conditions
were tested to assess assay performance. Serial dilutions of
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Fig. 1 Characterization of anti-α-syn antibodies. 50 ng of monomers (M) and fibrils (F) of human α-syn, ABri, Islet amyloid polypeptide (IAPP), Abeta or tau
(a), and β- or γ-syn (b) were spotted onto nitrocellulose membranes, and then probed with the indicated antibodies. c Representative photomicrographs
illustrating histopathological features detected with Syn-O2 in substantia nigra pars compacta (SNpc), CA2 and deep layers of entorhinal cortex (dENT) or
superficial layers of entorhinal cortex (sENT) of a PD patient (male, 84 years; Braak PD stage 6). 1) Lewy body and small bulgy neurites in SNpc; 2) neuron
with punctated Syn-O2 immunoreactivity in SNpc. *Note the Syn-O2 immunoreactive beaded strings. 3) long thin threads and many small extracellular or
synaptic Syn-O2 immunoreactivity; 4) a long thread in CA2 and many small neurites; 5) Lewy body pathology in deep layers of enthorinal cortex; 6) many
small neurites and synaptic staining (Bar = 50 μm). d Photomicrographs showing immunoreactivity of Syn-O2, KM-51 and Syn-1 monoclonal antibodies in
10 μm thick paraffin-embedded sections of a control and PD patient. No staining was observed in the control with any of these mAbs. In PD patient, small
and large LBs and LNs were observed with all three mAbs. With Syn-O2, many other long neurites and small extracellular or synaptic-like aggregates were
stained. Bar = 50 μm. e Monomeric (m-α-syn), oligomeric (o-α-syn), phosphorylated α-syn (p-Ser129-α-syn) and nitrated (n-α-syn) forms were used to test
the cross-reactivity of our antibodies 11D12 and Syn-140 · The generic commercial mAbs Syn-1 (BD Biosciences, 50 ng/ml) for α-syn, and EP1536Y (Abcam)
for p-Ser129-α-syn, were also included as controls. f 50 ng of recombinant α-, β- and γ-syn were loaded on SDS gels and transferred to nitrocellulose
membranes for western blotting, and then probed with our antibodies or control antibodies as appropriate. Syn-1 (BD Biosciences, 50 ng/ml)
for α-syn, anti-β-synuclein (8) (Santa Cruz Biotechnology, 1:2 K) for β-syn and C-20 (Santa Cruz Biotechnology, 1:3 K) for γ-syn. g 15 μg of human, mouse
and rat brain lysates were used in western blotting to test the specificity of 11D12 and Syn-140 · 50 ng of recombinant human α-syn (rec.α-syn) was
included as positive control. h 50 ng of recombinant human α-syn (H-α-syn) or mouse α-syn (M-α-syn), human phosphorylated α-syn (H-p-Ser129-α-syn)
and mouse phosphorylated α-syn (M-p-S129-α-syn) were loaded on SDS gels and transferred to nitrocellulose membranes for western blotting, and the
membranes were then probed with our mouse mAb (PS129) recognizes both human and mouse p-Ser129-α-syn or the generic commercial mAb Syn-1
as indicated
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recombinant human o-α-syn were run in duplicates. Based
on optimal sensitivity, specificity, reproducibility and back-
ground signal results, we selected a concentration of
0.2 μg/ml for coating (Fig. 4b). Our assay specificity towards
o-α-syn was further validated as no signal was detected
when serial dilutions of α-syn monomers were included
(Fig. 4c). The intra-assay and inter-assay precision was <
10 % (Fig. 4d). To assess the specificity and sensitivity of
our oligomeric-ELISA for o-α-syn in biological samples,
brain lysates and microdialysis fluid from young Tg mice
that over-expressed human α-syn were used, and WT and
KO mice were also included. As anticipated, o-α-syn levels
were significantly greater in Tg mice compared with WT,
whereas no signal was detected in KO mice (Fig. 4e). In
parallel, our assay quantified the levels of o-α-syn in hu-
man CSF successfully (Fig. 4e). Next, we spiked increasing
amounts of recombinant o-α-syn into human CSF sam-
ples. Interestingly, the average recovery rates were > 95 %
(Fig. 4f). We estimated that the lower limit of detection of
recombinant o-α-syn using this ELISA was as low as
10 pg/ml based on the initial concentration of the protein
(5 ng/ml). Taken together, the results show that our
oligomeric-ELISA is specific, sensitive and reproducible,
and it is thus suitable for the quantification of o-α-syn in
biological samples.
CSF biomarkers in diagnostic groups
We then measured the levels of different α-syn species in
human CSF of an independent cross-sectional cohort con-
sisting of individuals diagnosed with PD (Table 1) and age-
matched HC. Consistent with previous reports [11, 14, 16,
22], CSF t-α-syn levels were significantly decreased in PD
compared to HC (p < 0.0001), whereas, o-α-syn levels were
significantly higher in the PD group (p < 0.0001). CSF p-
S129-α-syn levels were elevated in PD compared to HC,
with considerable overlap between the groups (p <0.001).
However, both p-S129-/t-α-syn and o-/t-α-syn ratios im-
proved the discrimination of PD from HC (p < 0.0001).
CSF t-tau, p-tau and Aβ42 levels did not differ significantly
between PD and HC groups (Table 1).
Cross sectional correlation analysis of α-syn species in CSF
A positive correlation with t-α-syn was found for both
t-tau and p-tau (rs = 0.47, rs = 0.53 respectively, p < 0.00,
Fig. 5a, b) in the PD group. In contrast, an inverse sig-
nificant correlation was observed between p-S129-syn
levels and p-tau (rs = −0.30, p =0.043) within the PD
group. The levels of CSF o-α-syn did not correlate with
any of AD biomarkers (Table 2). While CSF t-α-syn did
not correlate with H&Y, UPDRS-III or disease duration,
an inverse correlation with MMSE scores was observed
(rs = −0.46, p < 0.001) within the PD group (Table 3).
Similarly, CSF p-S129-α-syn did not correlate with dis-
ease severity. On the other hand, a significant inverse
correlation was noted between CSF o-α-syn and H&Y
scores (rs = −0.37, p = 0.015, Fig. 5c) within PD group,
but not with UPDRS, disease duration or MMSE scores.
As anticipated, t-tau and p-tau positively correlated
with age (p = 0.003, p < 0.0001, respectively) and nega-
tively correlated with MMSE scores in the PD group
(rs = −0.35, p = 0.01, rs = −0.38, p = 0.009 respectively),
whereas, Aβ42 didn’t correlate significantly with any of
the clinical parameters.
Logistic regression analysis
Binary logistic regression analysis revealed five CSF bio-
markers as individual PD predictors: t-α-syn (p = 0.003),
o-α-syn (p <0.0001), p-S129-α-syn (p < 0.0001), o-/t-α-
syn ratio (p <0.0001) and p-S129/t-α-syn ratio (p <
0.0001; Fig. 6a-e). The combination of o-/t-α-syn, p-
S129-α-syn and p-tau formed the best fitting predictive
model for discriminating PD patients from controls
(Table 4). The sensitivity and specificity of the combin-
ation of o-/t-α-syn ratio, p-S129-α-syn and p-tau was
79 % and 67 % (AUC = 0.86). The performance of this
predictive model was significantly better compared to
o-/t-syn ratio, p-S129-syn alone (See Table 4 for further
details).
Discussion
The lack of reliable biomarkers is a major obstacle hold-
ing us back from accurately diagnosing PD or monitor-
ing its progression. Since the precise identification of
toxic α-syn species is still unclear, we aimed to generate
antibodies capable to detect wide range of the different
α-syn species including the pathogenic species o-α-syn
and p-S129-α-syn and then utilized these antibodies to
develop total-, oligomeric- and p-S129-ELISA systems
(See figure on previous page.)
Fig. 2 Validation of ELISA specific for total α-syn. a Histograms representing the optimization of the capture antibody (Syn-140) concentration. Based
on the sensitivity and background signal (BG), 0.1 μg/ml of the capture antibody was selected for subsequent assays. b Standard curves displaying the
specificities and sensitivities for α- (♦), β- (■) and γ-syn (▲). c Data shown are representative of 3 independent experiments using serial dilutions of
recombinant α-syn freshly prepared over 3 non-consecutive days. Measurements were taken in duplicate, and the results show the mean ± standard
deviation for each point, and the inter-assay coefficient of variation (CV) was < 10 %. d Antibody specificity determination using murine brain lysates
and human CSF; Tg, WT and KO brain lysates were diluted to 5 μg/ml. Our assay permitted the direct quantification of native α-syn in biological
samples such as human CSF and Tg mouse-brain lysates, whereas no signal was observed in WT or KO lysates. e Assessment of α-syn recovery rate in
human CSF. The recovery rates were calculated from measured α-syn concentrations relative to spiked amounts, and the assay consistently featured a
mean recovery rate > 90 %
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capable to quantify specifically these species in different
biological samples. Our novel antibody, Syn-O2, can
facilitate our ability to study o-α-syn and explore its
toxic characteristics. Moreover, Syn-O2 could provide
insights into the possible strategies through which we
can halt PD progression or reverse o-α-syn toxicity. Ap-
plying different immunoassays, Syn-O2 was shown to be
highly selective for o-α-syn since it did not cross-react
with aggregated forms of other amyloidogenic proteins
(tau, Abeta, IAPP and ABri) and it did not recognize the
other synuclein proteins (β- or γ-syn). Moreover, Syn-
O2 clearly stained LBs and LNs only. Most interestingly,
comparing Syn-O2 staining pattern with the other com-
mercial antibodies that are widely used in IHC (Syn-1,
KM-51), Syn-O2 not only showed a lack of cross-
reactivity with synaptic α-syn, but also detected pathology
not detectable by other pan antibodies confirming its spe-
cificity toward α-syn pathology.
Both Syn-140 and 11D12 are specific for α-syn, and while
Syn-140 recognizes α-syn from different species (human,
mouse and rat), 11D12 is specific only for human α-syn.
Moreover, PS129 specifically recognizes p-S129-α-syn
and does not cross-react with non-phosphorylated α-
syn. This diversity in the specifications/characteristics
of our antibodies imparts distinctive virtues to our
ELISA assays. Therefore, our assays can serve as power-
ful research tools to investigate the potential of α-syn
species in different biological samples. Furthermore,
our new ELISA assays provide multiple improvements
over other reported immunoassays. First, our ELISA
design using 384-well plates is perfectly compatible for
accommodating multiple replicates even with limited
volume of the sample (50 μl/well). Second, the en-
hanced sensitivity shown by our assays validates their
suitability for the analysis of human CSF specimens.
Our assays were shown to be highly target specific
based on several methods, including specificity valid-
ation of the employed antibodies to their respective an-
tigens, using brain and blood products from genetically
modified mice (Tg, WT, KO) and monitoring assay pre-
cisions. Our ELISAs are also robust since recovery rates
from spike experiments were > 90 %.
Our group has previously described the development
of an ELISA for quantifying o-α-syn in human CSF using
the same mouse mAb (211, mouse anti-α-syn antibody,
Santa Cruz) for capture and the biotinylated form of 211
for detection [14, 25]. However, heterophilic antibodies
may interfere in this assay format when using the
same antibody for capturing and detection, leading to
false-positive signals [26]. Our new oligomeric-ELISA
has addressed this shortcoming by using our novel
mouse conformation-specific mAb (Syn-O2), which
selectively captures o-α-syn, and a rabbit polyclonal
antibody (FL-140) for detection, thus permitting the
precise quantification of o-α-syn in biological samples.
Furthermore, our new oligomeric-ELISA system showed
great sensitivity and specificity for measuring α-syn oligo-
mers in biological samples in comparison to our previous
oligomeric-ELISA system.
Analyses of the cross sectional cohort revealed that
while concentrations of t-α-syn decreased, o-α-syn con-
centrations significantly increased in PD compared to
HC, consistent with other studies [11, 12, 16, 27–29].
The reduction in CSF t-α-syn is likely due to α-syn
oligomerisation and sequestration in LBs [11, 30], and
we speculate that the elevated levels of o-α-syn results
from a clearance failure of the aggregated forms of α-
syn. It’s worth mentioning, that in a recent study by
Compta et al. [29], the levels of o-α-syn were determined
using our previously published oligomeric-ELISA [14],
where o-α-syn levels were found to be elevated in PD
patients consistent with our findings in this study. How-
ever, we attribute the differences in the levels between
both studies to the use of different quantification methods,
pre-analytical confounding factors (types of tubes, spinning
conditions, storage conditions, etc.) and differences in dis-
ease severity between the patients included in the studies.
Furthermore, as emphasized above, we found our new
oligomeric-ELISA to be more reliable compared to the old
generation oligomeric-ELISA in terms of sensitivity, speci-
ficity and robustness.
PD patients with dementia were not enrolled in our
cohort, as reflected in the overall high MMSE scores
registered. These high MMSE scores could explain the
weakness of the correlation between MMSE scores and
t-α-syn levels and the lack of a correlation with Aβ42
levels. Interestingly, CSF o-α-syn levels showed modest
negative correlation with disease motor severity (H&Y
grade). This inverse correlation, although weak, suggests
that o-α-syn increases at the early stage of the disease
prior to the manifestation of the motor symptoms. Inter-
estingly, similar finding has been recently reported in
sporadic PD patients and PD cases with leucine-rich
repeat kinase 2 mutations [23].
(See figure on previous page.)
Fig. 3 Validation of ELISA specific for p-S129-α-syn. a Standard curves displaying the specificities and sensitivities for p-S129-α-syn (♦) and
non-phosphorylated α-syn (■). b Histograms representing the optimization of the capture antibody (Syn-140) concentration and the
background signal (BG). c Examination of inter-assay variability. Measurements were taken in duplicate, and the results show the mean ±
standard deviation for each point, and the inter-assay variability was found < 15 %. d Assessment of α-syn recovery rate in human CSF. The
recovery rates were calculated between 95 and 97 % from measured α-syn concentrations relative to spiked amounts
Majbour et al. Molecular Neurodegeneration  (2016) 11:7 Page 7 of 15
0200000
400000
600000
800000
1000000
1200000
5 2 1 0.5 0.2 0.1 0.05 0.02 0.01
RL
U/
Se
c
o- -syn (ng/ml)
Syn-O2 0.5 μg/ml Syn-O2 0.2 μg/ml Syn-O2 0.1 μg/ml
0
5000
10000
15000
20000
25000
30000
35000
40000
0.1 0.05 0.02 0.01
ba
e
0
100
200
300
400
500
600
700
800
900
1000
o-
-s
yn
 (
pg
/m
l)
KO WT Tg KO WT Tg CSF
Mouse brain lysates Mouse ECF Human
not- detectable
# 1 # 2 # 3 # 1 # 2 # 3 # 1 # 2 # 3 # 1 # 2 # 3 # 1 # 2 # 3 # 1 # 2 # 3 # 1 # 2 # 3
c
y = -2778.9x2 + 153091x + 1669.9
R² = 0.9999
0
100000
200000
300000
400000
500000
600000
700000
800000
0 1 2 3 4 5 6
R
L
U
/S
ec
protein concentration (ng/ml)
α-syn oligomers α-syn monomers
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
5 2 1 0.5
R
L
U
/S
ec
o- -syn (ng/ml)
Day 1 Day 2 Day 3 5 ng/ml CV : 3.9
2 ng/ml CV : 4.9
1 ng/ml CV : 5.5
0.5 ng/ml CV : 7.4
d
f
Fig. 4 (See legend on next page.)
Majbour et al. Molecular Neurodegeneration  (2016) 11:7 Page 8 of 15
An increase in p-S129-α-syn levels was also observed
in the PD group compared to HC. Although, approxi-
mately 90 % of accumulated α-syn in LBs consists of
p-S129-α-syn [31], it is not known whether phosphor-
ylation of α-syn promotes or prevents the formation of
toxic α-syn aggregates. To date there is only one re-
ported study, in which there was a weak positive cor-
relation between CSF p-S129-α-syn/t-α-syn ratio and
disease severity [15], however we did not observe such
relationship in our current study. These discrepancies
are likely due to several factors, including differences
in the assay platform (Luminex versus sandwich-
ELISA), collection and handling of the CSF samples
and/or heterogeneity of the patients included in the
studies.
Nevertheless, including both o-/t-α-syn and p-S129-/t-
α-syn ratios improved the ability to discriminate between
PD and HC, this was further enhanced by including p-tau,
emphasizing the usefulness of combining several CSF
biomarkers for diagnostic purposes.
Synucleinopathies and tauopathies show significant
clinical overlap, making the early diagnosis of PD more
challenging. This overlap necessitates a combination of
measurements of CSF α-syn species with key AD
biomarkers to improve diagnostic accuracy. Moreover,
several in vitro and in vivo studies investigated interac-
tions among α-syn and tau proteins, showing that these
proteins promote each other’s aggregation, leading to
neuronal degeneration and worsening cognitive impair-
ment [32]. The positive correlation between CSF t-α-syn
and t-tau and p-tau in the PD group we observed, con-
firms and extends reports by others showing a positive
correlation between CSF t-α-syn and tau levels in PD,
AD and controls [33].
Conclusions
In summary, using our novel mAbs, we have developed
sensitive and specific ELISAs to measure t-, o- and p-
S129-α-syn species in human CSF. Combining measure-
ments of different α-syn species in CSF, we observed
marked differential CSF patterns between PD and con-
trols. Our results validate the usefulness of combining
multiple CSF biomarkers in improving PD diagnostic
accuracy and prognosis. Although the potential use of
our assays was confirmed in an independent cohort, we
still need to validate the utilization of our assays in
large-scale, prospective, longitudinal and well-controlled
studies such as the ongoing Parkinson’s Progression
Markers Initiative, and by inclusion of patients with
other neurological illnesses.
Methods
Generation of anti-α-syn antibodies
Generation and purification of our mouse monoclonal
antibodies were performed as previously described [24].
Briefly, the antigens, recombinant human α-syn protein,
α-syn fibrils [34] or synthetic phosphopeptide-S129
(CYEMPSEEGY (α-syn aa 125 to 133; [35, 36]) were
used to generate 11D12, Syn-O2 and PS129 mouse
monoclonal antibodies respectively. The antigens were
repeatedly used to immunize female BALB/C mice sub-
cutaneously. Mice with appropriate plasma titers were
(See figure on previous page.)
Fig. 4 Validation of oligomeric-ELISA specific for α-syn oligomers. a Electron microscopy image of negatively stained sample of α-syn solution
containing soluble oligomers and protofibrils which was used as the ELISA standard. b Standard curves displaying the specificities and sensitivities
for α-syn oligomers (♦), and α-syn monomers (■). c Histograms representing the optimization of the capture antibody (Syn-O2) concentration.
d Assessment of inter-assay variability. Measurements were taken in duplicate, and the results show the mean ± standard deviation for each point,
and the intra-assay and inter-assay analysis revealed a CV of < 10 %. e Detection of o-α-syn in human CSF, Tg, WT and KO brain lysates. O-α-syn
levels were significantly greater in Tg mice compared with WT, whereas no signal was detected in KO mice. The assay also quantified successfully
the levels of o-α-syn in human CSF. f Assessment of o-α-syn recovery rate in human CSF. Recovery rates were calculated from measured o-α-syn
concentrations relative to spiked amounts and the average recovery rates were > 95 %
Table 1 Demographics, clinical features and biomarkers
HC (n = 48) PD (n = 46) p-values
Female 32 (66.6 %) 18 (39 %) 0.85
Male 16 (33.3 %) 28 (61 %)
Age 63 (57–67) 64 (57–71) 0.7969
Disease years - 4 (2–8.3) -
H&Y Stage - 2 (2–2.5) N.A
UPDRS- III - 23 (15.3–27) N.A
MMSE 29 (29–30) 29 (28–30) 0.0479
t-α-syn (ng/ml) 1.6 (1.3–2.2) 1.3 (1.2–1.6) <0.0001
p-S129-α-syn (pg/ml) 222 (180.5–275) 261 (206.8–296.3) <0.001
o-α-syn (pg/ml) 57 (36–106.5) 116 (76–170) <0.0001
p-S129/t-α-syn % 13.7 (9.2–18.5) 18.6 (15.7–23.3) <0.0001
o-/t-α-syn % 3.5 (2.3–6.2) 8.9 (5.2–12.2) <0.0001
t-tau (pg/ml) 229 (162–271.5) 190 (157.8–274.3) 0.1710
p-tau (pg/ml) 41.5 (29.3–50.3) 41.1 ± 16 0.5965
Aβ42 (pg/ml) 995.5 (877.5–1153) 966.5 (794–1077) 0.6745
Median, interquartile ranges and p-values of Mann-Whitney U test continuous
variables, Count (percentage) for categorical ones
Abbreviations: HC healthy controls, PD Parkinson’s disease, H&Y Hoehn and
Yahr, UPDRS- III Unified Parkinson’s Disease Rating Scale-Part-III, MMSE
mini-mental state examination, t-α-syn total α-synuclein, p-S129-α-syn
phosphorylated Ser 129 α-synuclein, o-α-syn oligomeric α-synuclein, t-tau
total-tau, p-tau phosphyorylated-tau, Aβ42 amyloid beta-42
Majbour et al. Molecular Neurodegeneration  (2016) 11:7 Page 9 of 15
euthanized and splenocytes were extracted and fused
with Sp2/0 myeloma cells and then seeded in HAT
(hypoxantin, aminopterine, and thymidine) selective
medium to generate antibody-producing hybridomas
according to standard techniques. After 10 days, the
medium was replaced with hypoxantin, thymidine
medium and 5 days later the culture supernatants were
tested for secreted anti-α-syn antibodies using indirect
ELISA. Several monoclonal antibodies were produced,
purified and thoroughly characterized, among which
Syn-O2 (IgG1), 11D12 (IgG2a) and PS129 (IgG2a) were
selected for this study. The isotypes were determined
using an isotyping kit (Sigma-Aldrich, USA) and the
r= 0.46
p<0.01
a
r= -0.37
p<0.05
c
r= 0.53
p<0.001
b
Fig. 5 Scatter plots showing the correlation between t-α-syn and t-tau, p-tau and between o-α-syn and Hoehn and Yahr score (H&Y) scores. The
correlation between CSF t-α-syn with t-tau (r =0 · 46, p < 0 · 01) and p-tau (r = 0 · 53, p < 0 · 001) in the PD group (a-b). The correlation between
CSF o-α-syn with H&Y scores (r = −0 · 37, p < 0 · 05) in the PD group (c). The dotted line is the 95 % prediction interval for the calculated regression
line (solid line)
Table 2 Spearman correlations between CSF biomarkers in PD
t-α-syn p-α-syn o-α-syn t-Tau p-Tau Aβ42
t-α-syn 1 · 00
p-S129-α-syn 0 · 002 1 · 00
o-α-syn 0 · 21 −0 · 03 1 · 00
t-Tau 0 · 46** −0 · 19 0 · 06 1 · 00
p-Tau 0 · 53*** −0 · 30* 0 · 14 0 · 86** 1 · 00
Aβ42 0 · 09 −0 · 14 0 · 5284 0 · 31* - 1 · 00
Abbreviations: t-α-syn total α-synuclein, p-S129-α-syn phosphorylated Ser 129
α-synuclein, o-α-syn oligomeric α-synuclein, t-tau total-tau, p-tau
phosphyorylated-tau, Aβ42 Amyloid Beta-42. (*p <0.05, **p <0.01, ***p <0.001)
Table 3 Spearman correlations between CSF biomarkers,
disease duration (years), UPDRS-III, Hoehn and Yahr stage and
MMSE in PD
Disease
years
UPDRS-
III
Hoehn and Yahr
stage
MMSE
t-α-syn 0 · 06 0 · 12 0 · 18 −0 ·
46**
p-S129-α-syn 0 · 04 −0 · 16 −0 · 18 −0 · 05
o-α-syn −0 · 25 −0 · 19 −0 · 37* −0 · 01
p-S129/t-α-syn
%
−0 · 16 −0 · 22 0 · 002 0 · 39**
o/t-α-syn % −0 · 25 −0 · 26 −0 · 31* 0 · 24
Abbreviations: t-α-syn total α-synuclein, p-S129-α-syn phosphorylated Ser 129
α-synuclein, o-α-syn oligomeric α-synuclein, UPDRS- III Unified Parkinson’s
Disease Rating Scale-Part-III, H&Y Hoehn and Yahr, MMSE mini-mental state
examination. (*p <0.05, **p <0.01, ***p <0.001)
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antibody purification was done using Protein G-agarose
(Sigma-Aldrich, USA) affinity chromatography.
Syn-140 is a sheep polyclonal antibody raised against full-
length human α-syn as previously described [37, 38]. In
brief, a polyclonal antiserum was raised against α-syn in
sheep by intramuscular injection into four sites of 500 μg
recombinant α-syn protein emulsified in Freund’s complete
adjuvant. Boosts of 200 μg in Freund’s incomplete adjuvant
were given intramuscularly into four sites at intervals after
the primary injection of 1 month, 2 months and 6 months.
The sheep were bled 8 days after the final boost.
Dot blot
Monomeric and aggregated forms of recombinant α-, β-
and γ-syn or tau proteins and synthetic peptides Aβ-42 [9,
39]; Islet Amyloid Polypeptide (IAPP) [40]; or ABri [35]
were used for testing the specificity of Syn-O2. Each pro-
tein/peptide was spotted (50 ng) onto a nitrocellulose
membrane and allowed to dry at RT for 1 h. The
membranes were then incubated for 1 h at RT with 5 %
skimmed milk in PBST (PBS containing 0.05 % Tween-20)
with gentle agitation. The blocking solution was then
removed, and the membranes were incubated for 2 h at
RT with the primary antibodies: Syn-O2; mouse anti-α-syn
(Syn-1, BD Bioscience); mouse anti-β-syn (8; Santa Cruz
Biotechnology); goat anti-γ-syn (C-20, Santa Cruz
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Fig. 6 Use of receiver operating curves (ROC) for the levels of α-syn species in CSF. ROC curves based on logistic regression analyses for the
classification of PD patients versus HC based on various predictors and combination of predictors. (a) t-α-syn, (b) o-α-syn, (c) p-S129-α-syn, (d)
o-/t-α-syn% and (e) p-S129-/t-α-syn%
Table 4 Logistic regression analysis of CSF biomarkers between
PD and HC
Predictor AUC Sensitivity Specificty p value
t-α-syn 0 · 70 65 % 74 % 0 · 001
p-S129-α-syn 0 · 67 65 % 54 % <0 · 0001
o-α-syn 0 · 77 89 % 52 % < 0 · 0001
p-S129/t-α-syn % 0 · 76 80 % 56 % < 0 · 0001
o-/t-α-syn % 0 · 82 68 % 85 % < 0 · 0001
o-/t-α-syn %, p-S129-α-syn
& p-tau
0 · 86 79 % 67 % < 0 · 0001
Abbreviations: t-α-syn total α-synuclein, p-S129-α-syn phosphorylated Ser 129
α-synuclein, o-α-syn oligomeric α-synuclein, p-tau phosphorylated-tau, AUC
area under the curve
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Biotechnology); mouse anti-tau (5E2, Millipore); mouse
anti-amyloid beta (82E1, IBL) or mouse anti-amylin (R10/
99, Santa Cruz Biotechnology). The membranes were then
washed three times with PBST and incubated with second-
ary antibodies, goat anti-mouse HRP (1:20 K, Jackson
Immunoresearch, PA, USA); goat anti-rabbit (1:20 K,
Jackson Immunoresearch, PA, USA) or chicken anti-
goat HRP (1:30 K, Santa Cruz Biotechnology) as appro-
priate for 1 h at RT. The membranes were then washed
three times with PBST and developed using SuperSignal
West Pico Chemiluminescent Substrate (Pierce).
Western blotting
Samples of human-, mouse- and rat-brain lysates (15 μg),
recombinant α-, β- and γ-syn or human and mouse p-
S129-α-syn (50 ng) were mixed with loading buffer
(250 mM Tris-HCl, pH 6.8, 30 % glycerol, 0.02 % bromo-
phenol blue) and then separated on 15 % SDS-PAGE gels.
The separated proteins were transferred to 0.45 μm nitro-
cellulose membranes (WhatmanGmbh-Germany) at
100 V for 45 min. The membranes were boiled for 5 min
in PBS and then blocked for 1 h with 5 % non-fat milk
prepared in PBST prior to incubation with 10 ml of pri-
mary antibody (50 ng/ml) for 2 h at RT. The membranes
were then washed 4 times with PBST followed by incuba-
tion with the secondary antibody. After one hour, the
membranes were washed 4 times with PBST, and immu-
noreactive bands were visualized using the SuperSignal
West Pico Chemiluminescent Substrate Kit (Pierce) ac-
cording to the manufacturer’s instructions.
Preparation of the standard for the oligomeric ELISA
Expression and purification of recombinant human α-
syn was performed as previously described [34]. α-Syn
oligomers were prepared by incubating fresh α-syn
(25 μM) with Ginsenoside Rb1 (100 μM) in PBS at 37 °C
for 5 days with continuous shaking at 800 rpm in a
Thermomixer (Eppendorf), then α-syn oligomers were
characterized using electron microscopy as previously de-
scribed [41]. Briefly, size exclusion chromatography was
carried out using an AKTA FPLC system (GE Healthcare,
Sweden) and a Superdex 200 column at 4 °C, in order to
separate soluble α-syn oligomers from monomers. This
way, we guaranteed that only pure soluble α-syn oligomers
were separated and then confirmed by electron micros-
copy (Fig. 4a) [41].
Development of ELISA for measuring t-α-syn in human
CSF
A 384-well ELISA microplate (Nunc MaxiSorb, NUNC)
was coated by overnight incubation at 4 °C with 0.1 μg/ml
Syn-140 (sheep anti-α-syn polyclonal antibody) in 200 mM
NaHCO3, pH 9.6 (50 μl/well). The plate was then washed
with PBST and incubated with 100 μl/well of blocking
buffer (PBST containing 2.5 % gelatin) for 2 h at 37 °C.
After washing, 50 μl of the CSF samples (thawed on ice
and Tween-20 was added to a final concentration of
0.05 %) was added to each well, and plates were incubated
at 37 °C for 2.5 h. 11D12 (mouse anti-α-syn monoclonal
antibody), diluted in blocking buffer at 1:5 K was added to
the appropriate wells, and incubated at 37 °C for 2 h. Next,
the plate was washed and incubated for 2 h at 37 °C with
50 μl/well of species-appropriate secondary antibody
(donkey anti-mouse IgG HRP, Jackson ImmunoResearch)
diluted in blocking buffer (1:20 K). After washing, the
plate was incubated with 50 μl/well of an enhanced
chemiluminescent substrate (SuperSignal ELISA Femto,
Pierce Biotechnology, Rockford, IL). The chemilumines-
cence, expressed in relative light units, was immediately
measured using VICTOR™ X3 multilabel plate reader
(PerkinElmer). The standard curve for the ELISA assay
was carried out using serial dilutions of recombinant
human α-syn in artificial CSF.
Development of ELISA for measuring p-S129-α-syn in
human CSF
A 384-well ELISA microplate (Nunc MaxiSorb, Nunc)
was coated by overnight incubation at 4 °C with 0.5 μg/
ml Syn-140 (sheep anti-α-syn polyclonal antibody) in
200 mM NaHCO3, pH 9.6 (50 μl/well). The plate was
then washed with PBST and incubated with 100 μl/well
of blocking buffer for 2 h at 37 °C. After washing, 50 μl
of the CSF samples (thawed on ice and Tween-20 was
added to a final concentration of 0.05 %) was added to
each well, and plates were incubated at 37 °C for 2.5 h.
PS129 (mouse anti-pS129-α-syn monoclonal antibody)
diluted in blocking buffer (1:1 K) were added to the
appropriate wells, and incubated at 37 °C for 2 h. Next,
the plate was washed and incubated for 2 h at 37 °C
with 50 μl/well of species-appropriate secondary anti-
body (donkey anti-mouse IgG HRP (Jackson Immu-
noResearch)) diluted in blocking buffer (1:20 K). After
washing, the plate was incubated with 50 μl/well of an
enhanced chemiluminescent substrate (SuperSignal
ELISA Femto, Pierce Biotechnology, Rockford, IL).
The chemiluminescence, expressed in relative light
units, was immediately measured using VICTOR™ X3
multilabel plate reader (PerkinElmer). The standard
curve for the ELISA assay was obtained using serial di-
lutions of recombinant human p-S129-α-syn in artifi-
cial CSF (50 μl/well).
Development of ELISA for measuring o-α-syn in human
CSF
A 384-well ELISA microplate (Nunc MaxiSorb, Nunc)
was coated by overnight incubation at 4 °C with Syn-O2
(0.2 μg/ml) in 200 mM NaHCO3, pH 9.6 (50 μl/well).
The plate was then washed with PBST and incubated
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with 100 μl/well of blocking buffer for 2 h at 37 °C. After
washing, 50 μl of the CSF samples (thawed on ice and
Tween-20 was added to a final concentration of 0.05 %)
was added to each well, and plates were incubated at
37 °C for 2.5 h. FL-140 (rabbit polyclonal antibody, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), diluted in
blocking buffer at 1:1 K, was added to the appropriate
wells, and incubated at 37 °C for 2 h. Next, the plate was
washed and incubated for 2 h at 37 °C with 50 μl/well of
goat anti-rabbit IgG HRP (Jackson ImmunoResearch) di-
luted in blocking buffer (1:15 K). After washing, the
plate was incubated with 50 μl/well of an enhanced
chemiluminescent substrate (SuperSignal ELISA Femto,
Pierce Biotechnology, Rockford, IL). The chemilumines-
cence, expressed in relative light units, was immediately
measured using VICTOR™ X3 multilabel plate reader
(PerkinElmer). The standard curve for the ELISA assay
was obtained using serial dilutions of recombinant hu-
man o-α-syn in artificial CSF (50 μl/well).
AD CSF biomarkers
Concentrations of t-tau, p-tau and Aβ42 in CSF were de-
termined using the sandwich ELISAs Innotest β-Amyloid
(1–42), Innotest h TAU-Ag™ and Innotest Phosphotau
(181P)™; (Fujirebio Diagnostics), respectively, as described
previously [42].
Study population
A description of this cross-sectional cohort has been
previously published [27]. We included 46 patients with
PD that attended the outpatient clinic for movement dis-
orders at the VU University Medical Center (VUMC)
between September 2008 and February 2011, and 48
self-declared age-matched HC who were recruited via an
advertisement in the periodical of the Dutch Parkinson
Foundation. All patients with PD fulfilled the United
Kingdom Parkinson’s Disease Society Brain Bank clinical
diagnostic criteria [43]. Patients were included only if
they were able to understand the study aim and proce-
dures. Mini-Mental State Examination and/ or neuro-
psychological assessment in the patients did not indicate
dementia. In the controls, dementia was excluded using
the Cambridge Cognitive Examination scale [44]. Patients
and controls underwent a standardized clinical assessment
that included their medical history and a neurological
examination. Severity of parkinsonism and disease stage
in the ‘on’ state were rated using the Unified Parkinson’s
Disease Rating Scale-Part-III (UPDRS-III) [45] and the
modified Hoehn and Yahr (H&Y) classification [46], re-
spectively. All the samples were screened in a blinded
fashion and were tested randomly. All the results were
confirmed using at least two independent experiments. A
series of internal controls were also run to check for
run-to-run variations. All CSF samples with > 500
erythrocytes/μl were excluded from analysis as traces of
blood may influence CSF α-syn levels [47].
Data analysis
Statistical analyses were performed using using Graph-
Pad Prism (version 5.0) software and IBM SPSS software
21. Continuous variables were described using medians
and interquartile ranges. Categorical variables were pre-
sented as count or percentages. Mann-Whitney U-test
was used for comparisons between PD and HC diagnos-
tic groups. Correlations were calculated using Spear-
man’s Rho (r). Subjects with PD and HC were matched
for age (p = 0 · 002), but not for gender since no signifi-
cant differences between CSF biomarkers in males and
females were found in PD or HC groups (p = 0 · 85). The
accuracy of the diagnostic value of the biomarkers was
assessed based on the area under the curve (AUC) of the
receiver operating characteristic (ROC) curve [48]. Cut-
off values were calculated using sensitivity and specificity
values that maximized Youden’s index (sensitivity + spe-
cificity − 1). To determine the diagnostic value of a com-
bination of multiple biomarkers, we performed a binary
logistic regression analysis. Combinations of biomarkers
were tested to find the best fitting model in a forward
stepwise mode, which was based on the change in likeli-
hood resulting from including the variable. Change in -2
log-likelihood statistics between the models was tested
using Chi-square (χ2) tests. Sensitivity and specificity
values of the combinations of biomarkers for PD diagno-
sis and progression values were also calculated.
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